Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K012590
    Manufacturer
    Date Cleared
    2001-09-07

    (28 days)

    Product Code
    Regulation Number
    876.5010
    Reference & Predicate Devices
    Why did this record match?
    Reference Devices :

    K012090, K012056, K971448, K981407, K991028

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Cordis PALMAZ® GENESIS™ Transhepatic Biliary Stent on OPTA™ PRO .035" Delivery System is indicated for use in the palliation of malignant neoplasms in the biliary tree.

    Device Description

    The PALMAZ GENESIS Transhepatic Biliary Stent is a balloon-expandable, laser cut stent made from 316L Stainless Steel tubing. The stent is sold mounted on a Cordis percutaneous transluminal angioplasty (PTA) balloon catheter. The stent is provided in nominal, unexpanded stent lengths from 19 to 79 mm. The stent is designed for expansion to diameters from 8 to 10 mm, depending on the diameter of the associated balloon upon which it is mounted.

    The Cordis OPTA PRO PTA balloon catheter, formerly known as the OPTA LP PTA Balloon Catheter, is used as a delivery system for the PALMAZ GENESIS Transhepatic Biliary Stent. The delivery system utilizes an over-the-wire design and is a catheter with a distal DURALYN™ balloon and a proximal Y-connector. Two radiopaque marker bands aid in stent placement. The injectate lumen (marked "THRU") is used to inject contrast medium via hand injection, and to track the catheter over a guide wire. The inflation lumen (marked "BALLOON") is used to inflate and deflate the balloon. The nominal balloon size is printed on the Y-connector.

    A metal introducer tube is included in the packaging.

    The PALMAZ GENESIS Transhepatic Biliary stent on OPTA PRO .035" Delivery System is provided sterile (via ethylene oxide) and is intended for single use only.

    AI/ML Overview

    The provided document is a 510(k) Premarket Notification for the "Cordis PALMAZ® GENESIS™ Transhepatic Biliary Stent on OPTA™ PRO .035" Delivery System". This type of submission is for medical devices and focuses on demonstrating substantial equivalence to a legally marketed predicate device, rather than proving novel efficacy or performance through extensive clinical trials. Therefore, the information typically requested for AI/device performance studies (like acceptance criteria, sample sizes for test/training sets, ground truth establishment, expert qualifications, adjudication methods, or MRMC studies) is generally not included or applicable in this context.

    Here's an breakdown based on the provided text, addressing your questions to the extent possible given the nature of the document:

    1. Table of Acceptance Criteria and Reported Device Performance

    Feature/TestAcceptance CriteriaReported Device Performance
    Overall Safety and EffectivenessSubstantial equivalence to predicate devices (K012090, K012056, K971448, K981407, K991028).Demonstrated via data collected from non-clinical design verification tests and analyses. (Specific performance metrics are not detailed in this summary.)
    Intended UseDevice is able to be used for the palliation of malignant neoplasms in the biliary tree.The device is indicated for this use, implying it meets the necessary functional requirements.
    Vascular System Use (Limitations)Not established (as per FDA determination).N/A - This is a limitation, not a performance criterion.

    Explanation: In a 510(k) submission for a device like this stent and delivery system, the "acceptance criteria" are typically related to meeting design specifications, demonstrating biocompatibility, sterilization efficacy, and functional integrity through non-clinical bench testing. The primary "performance" is its ability to meet the stated intended use and its substantial equivalence to predicate devices. The document explicitly states "Performance standards have not been established for this device by the FDA under section 514 of the Food, Drug and Cosmetic Act."

    2. Sample size used for the test set and the data provenance

    • Sample Size for Test Set: Not specified. The document states "data collected from non-clinical design verification tests and analyses." This typically refers to bench testing of device components, and the "sample size" would relate to the number of devices or components tested to verify specifications (e.g., stent expansion diameter, balloon integrity, delivery system trackability, etc.). These details are not provided in this summary.
    • Data Provenance: The data is from "non-clinical design verification tests and analyses," implying laboratory and engineering testing. No mention of human clinical data or its geographical origin is made.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    • Not Applicable. This is a medical device 510(k) submission, not an AI performance study requiring expert adjudication for ground truth. Technical specifications and functional tests would be verified against engineering standards and design requirements.

    4. Adjudication method for the test set

    • Not Applicable. See point 3. Testing would follow standard engineering and quality control procedures, not expert adjudication in the context of diagnostic performance.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done

    • No. An MRMC study is relevant for diagnostic devices, particularly those involving image interpretation with AI assistance. This document describes a physical medical device (stent and delivery system) and its mechanical/functional performance, not a diagnostic tool requiring human reader comparison.

    6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

    • Not Applicable. This refers to AI algorithm performance. The device described is a physical medical implant and delivery system, not an algorithm.

    7. The type of ground truth used

    • For the non-clinical design verification, the "ground truth" would be established by the device's design specifications and engineering requirements (e.g., material properties, dimensional tolerances, force requirements, fluid flow rates, etc.). These are verified through various physical and chemical tests.

    8. The sample size for the training set

    • Not Applicable. This refers to AI/machine learning. The device described does not involve a "training set" in this context.

    9. How the ground truth for the training set was established

    • Not Applicable. See point 8.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1